Home

GARY A LYONS

CIK 1123343 · President and CEO · last filed 2026-08-19

GARY A LYONS is a President and CEO who has filed 155 SEC Form 4 insider transactions across 13 companies since 2007. The most recent filing, for TVTX, was dated Aug 19, 2026. Across all open-market trades the lifetime net is −$25.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $20.9M across reported positions. 95 SEC filings were submitted jointly with NEUROCRINE BIOSCIENCES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$20.94M

Companies

13

Total Filings

155

Lifetime Open-Market Net

-$24.97M

Filer Profile

Reported Address
6027 EDGEWOOD BEND COURT
C/O NEUROCRINE BIOSCIENCES
SAN DIEGO, CA 92130
State of Incorporation
DE
Related Filers
NEUROCRINE BIOSCIENCES INC — 95 joint filings, latest 2026-05-29
ABBOTT BIOTHERAPEUTICS CORP — 5 joint filings, latest 2010-04-23
PDL BIOPHARMA, INC. — 3 joint filings, latest 2008-08-15
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
TVTX Director 62,400 $59.41 $3.71M -$1.55M 9 2026-08-19
NBIX Director 122,141 $137.94 $16.85M -$23.43M 57 2026-05-29
RIGL Director 7,500 $48.26 $361.9K $0 16 2023-07-12
ELDN Director — $2.66 — $0 3 2023-05-02
Fresh Tracks Therapeutics, Inc. (BBI) Delisted Director 417 $2.35 $980 $0 10 2022-05-17
Eledon Pharmaceuticals, Inc. (NVUS) Delisted Director — — — $0 4 2020-09-15
Travere Therapeutics, Inc. (RTRX) Delisted Director 34,000 — — $0 7 2020-05-19
Fresh Tracks Therapeutics, Inc. (VICL) Delisted Director 1,118 — — $15.3K 13 2018-05-24
PLUS THERAPEUTICS, INC. (CYTX) Delisted Director 5,985 — — $0 7 2018-02-09
HUMANIGEN, INC (KBIO) Delisted Director — — — $0 2 2015-07-14
PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted Director 206,145 — — $0 7 2011-07-12
FACT Director 2,500 $10.72 $26.8K $0 3 2010-04-21
PDL BIOPHARMA, INC. (PDLI) Delisted Director — — — $0 2 2008-08-15

Recent Filings

155 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 TVTX Mixed — -$458.4K EDGAR
2026-08-18 TVTX Notice (144) −5,000 -$317.6K EDGAR
2026-08-17 TVTX Notice (144) −5,000 -$310.7K EDGAR
2026-05-29 NBIX Grant (A) — $0 EDGAR
2026-05-21 NBIX Exer (M) +1,659 $0 EDGAR
2026-05-21 TVTX Grant (A) +4,000 $0 EDGAR
2026-04-16 TVTX Mixed — -$197.9K EDGAR
2026-04-14 TVTX Notice (144) −8,000 -$245.6K EDGAR
2025-12-04 NBIX Mixed — -$1.57M EDGAR
2025-12-03 NBIX Notice (144) −15,000 -$2.29M EDGAR
Showing 1–10 of 155
Page 1 of 16
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.